IP Library Granted Patent US 9,181,280
Granted Patent B2
US 9,181,280 · App. 14/250,936 · Granted Nov 10, 2015

Factor VIIa inhibitor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,280
App. No.
14/250,936
Granted
Nov 10, 2015
Kind
B2
Abstract

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

Claims (13)

1. A method of effecting clotting in an individual in need thereof, comprising administering to the individual an isolated compound of Formula Ib:

or a zwitterion thereof or a pharmaceutically acceptable salt thereof;

substantially free of the opposite enantiomer of the compound of Formula Ib.

2. A method of effecting clotting in an individual in need thereof, comprising administering to the individual a pharmaceutical composition comprising:

a. an isolated compound of Formula Ib:

or a zwitterion thereof or a pharmaceutically acceptable salt thereof;

substantially free of the opposite enantiomer of the compound of Formula Ib; and

b. a pharmaceutically acceptable carrier or excipient.

3. The method of claim 2 , wherein the pharmaceutical composition is formulated for parenteral administration.

4. The method of claim 2 , wherein the pharmaceutical composition is formulated for intravenous or subcutaneous administration.

5. The method of claim 2 , wherein the pharmaceutical composition further comprises an additional active ingredient.

6. The method of claim 2 , wherein the pharmaceutical composition comprises water.

7. The method of claim 2 , wherein the pH of the pharmaceutical composition is adjusted to a pharmaceutically acceptable pH.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0368. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME. Recorded May 18, 2016
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 038742/0371 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0359. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded May 17, 2016
From: OXFORD AMHERST CORPORATION; PHARMACYCLICS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 038742/0064 →
MERGER Recorded Jul 16, 2015
From: OXFORD AMHERST CORPORATION
To: PHARMACYCLICS, INC.
Reel/Frame 036126/0359 →
MERGER AND CHANGE OF NAME Recorded Jul 16, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036126/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2014
From: DICKMAN, DANIEL A.; KUMAR, DANGE VIJAY; O'BRYAN, COLIN; RAI, ROOPA; SHRADER, WILLIAM DVORAK; WESSON, KIERON
To: AXYS PHARMACEUTICALS, INC.
Reel/Frame 032664/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2014
From: AXYS PHARMACEUTICALS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 032665/0155 →